<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663973</url>
  </required_header>
  <id_info>
    <org_study_id>GBECAM 0115</org_study_id>
    <nct_id>NCT02663973</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III</brief_title>
  <official_title>Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avon Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal goal of this study is to describe the epidemiology of breast cancer in the
      Brazilian population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal goal of this study is to describe the epidemiology of breast cancer in the
      Brazilian population. Other specific goals are:

        -  To evaluate the demographic and socio-demographic profile, comorbidities and
           reproductive risks, anthropometric profile and family history.

        -  Characterize the breast tumors immunophenotype through anatomopathological data, such
           as: tumor grade, estrogen receptor, progesterone receptor, HER2, Ki67.

        -  Describe the screening tests, main symptoms and cancer stage in the moment of the
           diagnosis.

        -  Describe the initial cancer treatment and locally advanced such as surgery,
           radiotherapy, chemotherapy and endocrine therapy.

        -  Describe palliative treatment for recurrent or metastatic breast cancer: chemotherapy,
           radiotherapy, biphosphonate, and others.

        -  Evaluate the clinical outcomes such as: local or diffuse relapse, period of time until
           progression to metastatic cancer, global lifespan and specific breast cancer lifespan.

        -  Evaluate clinical complications of the metastatic disease, such as: brain metastasis,
           spinal cord compression, skeletal related events.

        -  Analyze the demographical and socio-economical characteristics, clinical-pathological
           characteristics of the tumor, treatment, clinical outcomes, type of institution
           (private/public), and other factors that may impact clinical outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the epidemiology of breast cancer in the Brazilian population</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the socioeconomical characteristics of the Brazilian population with breast cancer</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the immunophenotypic markers of the tumor</measure>
    <time_frame>Annually, during 5 years</time_frame>
    <description>estrogen receptor, progesterone receptor, HER2, Ki67</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of breast cancer staging</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of screening tests of breast cancer patients in Brazil</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main symptoms presented by patients with breast cancer in Brazil</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial treatment for breast cancer of Brazilian patients</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of palliative treatment for metastasis or recurrent breast cancer in Brazilian patients</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome of Brazilian breast cancer patients</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of clinical complications displayed by breast cancer Brazilian patients</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of exterior factors that may impact clinical outcome of breast cancer Brazilian patients</measure>
    <time_frame>Annually, during 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Woman ≥ 18 years old with recent diagnosis of breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman ≥ 18 years old

          -  Invasive breast cancer stage I to IV proven by histology or cytology

          -  Patients with new pathological diagnosis of invasive primary BC after the site
             activation date

          -  Pathological diagnosis of invasive breast cancer during recruitment (6 months before
             center activation or until 3000 patients included)

          -  New primary cancer on the same breast or contralateral breast.

          -  Patient's medical chart is available and adequate for data collection

          -  Patient properly signed the informed consent form
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica AMO</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Dybal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Núcleo de Oncologia da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarissa Mathias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Regional Integrado de Oncologia (CRIO)</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Henrique Cronenberger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Setor de Ginecologia e Mama do Hospital Araújo Jorge</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldo Queiroz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade de Pesquisa Clínica/Hospital de Clínicas da UFG</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruffo Freitas Júnior, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade de Pesquisa Clínica do Hospital do Câncer de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Couto Filho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Jardim Amália</name>
      <address>
        <city>Volta Redonda</city>
        <state>Rio de Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viviane Lima</last_name>
    </contact>
    <investigator>
      <last_name>Heloísa Resende, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica da Liga Norte Riograndense Contra o Câncer</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande do Norte</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Emerenciano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas da Serra Gaúcha</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Binotto</last_name>
    </contact>
    <investigator>
      <last_name>Tomás Reinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínicas para Estudos Multicêntricos da UCS</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Reiriz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade de Passo Fundo - Clínica CITO</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lazaretti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovana Vacaro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo de Estudos em Pesquisa de Pelotas</name>
      <address>
        <city>Pelotas</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiane Petrarca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CPO - Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Barrios, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Rosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novos Tratamentos em Câncer - Hospital Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Zereu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEPON</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeni Nerón, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica de Neoplasias Litoral - Centro de Novos Tratamentos Itajaí</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliano Borges, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico de Ribeirão Preto - InORP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diocésio de Andrade, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional do Câncer</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Bines, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncoclínica</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Crocamo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sérgio Simon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Instituto do Câncer Arnaldo Vieira de Carvalho</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Van Eyil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital AC Camargo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladmir Lima, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://globocan.iarc.fr/Pages/fact_sheets_population.aspx</url>
    <description>World Health Organization. GLOBOCAN 2012: cancer incidence and mortality worldwide. Accessed in Jan 8 2015.</description>
  </link>
  <link>
    <url>http://www.cancer.gov/cancertopics/treatment</url>
    <description>National Cancer Institute. Cancer treatment. Accessed in Jan 8 2015.</description>
  </link>
  <reference>
    <citation>Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26. Erratum in: Lancet. 2015 Mar 14;385(9972):946.</citation>
    <PMID>25467588</PMID>
  </reference>
  <reference>
    <citation>Freitas-Junior R, Gonzaga CM, Freitas NM, Martins E, Dardes Rde C. Disparities in female breast cancer mortality rates in Brazil between 1980 and 2009. Clinics (Sao Paulo). 2012 Jul;67(7):731-7.</citation>
    <PMID>22892915</PMID>
  </reference>
  <reference>
    <citation>Gonzaga CM, Freitas-Junior R, Souza MR, Curado MP, Freitas NM. Disparities in female breast cancer mortality rates between urban centers and rural areas of Brazil: ecological time-series study. Breast. 2014 Apr;23(2):180-7. doi: 10.1016/j.breast.2014.01.006. Epub 2014 Feb 4.</citation>
    <PMID>24503143</PMID>
  </reference>
  <reference>
    <citation>Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, Bandera EV, Borges V, McKinnon C, Haiman CA, Lunetta K, Kolonel LN, Rosenberg L, Olshan AF, Ambrosone CB. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 2014 Sep 15;106(10). pii: dju237. doi: 10.1093/jnci/dju237. Print 2014 Oct.</citation>
    <PMID>25224496</PMID>
  </reference>
  <reference>
    <citation>Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011 Mar 16;103(6):470-7. doi: 10.1093/jnci/djr030. Epub 2011 Feb 23.</citation>
    <PMID>21346227</PMID>
  </reference>
  <reference>
    <citation>Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014 Feb;144(1):1-10. doi: 10.1007/s10549-014-2852-7. Epub 2014 Jan 30. Review.</citation>
    <PMID>24477977</PMID>
  </reference>
  <reference>
    <citation>Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007 Sep;8(5):395-408. Review.</citation>
    <PMID>17716297</PMID>
  </reference>
  <reference>
    <citation>Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38.</citation>
    <PMID>12711737</PMID>
  </reference>
  <reference>
    <citation>Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134. Epub 2007 Nov 6.</citation>
    <PMID>17986716</PMID>
  </reference>
  <reference>
    <citation>Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1803-11.</citation>
    <PMID>17855698</PMID>
  </reference>
  <reference>
    <citation>Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011 Apr 15;117(8):1602-11. doi: 10.1002/cncr.25746. Epub 2010 Nov 29.</citation>
    <PMID>21472708</PMID>
  </reference>
  <reference>
    <citation>Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52.</citation>
    <PMID>10963602</PMID>
  </reference>
  <reference>
    <citation>Liedke PE, Finkelstein DM, Szymonifka J, Barrios CH, Chavarri-Guerra Y, Bines J, Vasconcelos C, Simon SD, Goss PE. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):126-33. doi: 10.1158/1055-9965.EPI-13-0693. Epub 2013 Oct 28.</citation>
    <PMID>24165578</PMID>
  </reference>
  <reference>
    <citation>Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Illinois: A division of human Kinetics Publishers Inc, 1988.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

